Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of sevabertinib (BAY 2927088) in HER2-mutated solid tumors (panSOHO)
jRCT2011240072Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of sevabertinib in colorectal cancer (CRC), biliary cancer, bladder cancer and 5 more, sponsored by Bayer. Primary endpoint: Objective Response Rate by BICR. Started Mar 2025; status: recruiting.
02
Drugs
sevabertinib
03
Conditions
colorectal cancer (CRC)biliary cancerbladder cancertransitional cell carcinoma (TCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2011240072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240072.